Results 1 to 10 of about 70,105 (273)
Epigenetics and cell death: DNA hypermethylation in programmed retinal cell death. [PDF]
, 2013 BackgroundVertebrate genomes undergo epigenetic reprogramming during development and disease. Emerging evidence suggests that DNA methylation plays a key role in cell fate determination in the retina.
Enke, Raymond A +5 more
core +19 more sources
PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression [PDF]
, 2015 To overcome cancer cells resistance to pharmacological therapy, the development of new therapeutic approaches becomes urgent. For this purpose, the use of poly(ADP-ribose) polymerase (PARP) inhibitors in combination with other cytotoxic agents could ...
CAIAFA, Paola +11 more
core +12 more sources
Journal of Medical Case Reports, 2021 Background Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer.
Rosa Montero-Macias +12 more
doaj +1 more source
Pyridazine Based Compounds with PARP-1 Inhibitory Activity
Archives of Pharmaceutical Sciences Ain Shams University, 2023 Pyridazine-containing compounds have been identified as potent PARP1 inhibitors. The PARP is a family of enzymes essential for many cellular processes such as DNA repair, genomic stability, and apoptosis, also known as poly(ADP-ribose) synthetases and ...
Norhan A. Abdelrahman +3 more
doaj +1 more source
Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date [PDF]
Seminars in Radiation Oncology, 2022 Radiation resistance remains a huge clinical problem for cancer patients and oncologists in the 21st century. In recent years, the mammalian DNA damage response (DDR) has been extensively characterized and shown to play a key role in determining cellular survival following ionizing radiation exposure.
Derby, Sarah J. +2 more
openaire +2 more sources
The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer
Nowotwory, 2022 Genome instability and mutations are the hallmarks of cancer. Mutations within BRCA genes increase the risk of pancreatic cancer (PC) development. Poly(ADP-ribose) polymerase inhibitors (PARPi) show the synthetic lethality phenomenon in tumoral cells ...
Katarzyna Zubik +3 more
doaj +1 more source
Journal of Infection in Developing Countries, 2022 Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
Dimitra Ioanna Lampropoulou +6 more
doaj +1 more source
Adverse events of targeted therapies approved for women's cancers
International Journal of Women's Dermatology, 2021 Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle ...
Mathilde Saint-Ghislain, MD +2 more
doaj +1 more source
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma [PDF]
Current Opinion in Oncology, 2014 In 2012, two publications revealed a particular sensitivity of Ewing sarcoma cells to the inhibition of poly(ADP-ribose) polymerase (PARP). This review updates the reader on PARP function, the development of PARP inhibitors (PARPi) and the evidence for targeting PARP in Ewing sarcoma.
Vormoor B, Curtin NJ
openaire +3 more sources
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
BMC Cancer, 2020 Background Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for treating patients with high-grade serous ovarian cancer.
Kyung Jin Eoh +6 more
doaj +1 more source